Hy 03

PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE equired to respond to a collection of information unless it displays a valid OMB control number e a plus sign (+) inside this box Under the Paperwork Reduction Act of 1995, no persons are required to resp

TRANSMITTAL **FORM**

(To be used for all correspondence after initial filing)

S	pond to a collection of information unless	it displays a valid OMB control number.
	Application Number	10/058,821
	Filing Date	January 29, 2002
	First Named Inventor	Orest W. Blaschuk
	Group Art Unit	Not Yet Assigned
	Examiner Name	Not Yet Assigned
	Attorney Docket No.	100086.401C12

ENCLOSURES (check all that apply)									
Fee Transmittal Form Fee Attached Amendment/Response After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement; Form PTO-1449 Cited References (4) Certified Copy of Priority Document(s) Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 Response to Missing Parts/Incomplete Application	Assignment Papers (for an Application) Drawing(s) Request for Corrected Filing Receipt Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation, Change of Correspondence Address Declaration Statement under 37 CFR 3.73(b) Terminal Disclaimer Small Entity Statement Request for Refund	CD(s), Number of CD(s) After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Return Postcard Additional Enclosure(s) (please identify below):							
<u>Remarks</u>									
	RE OF APPLICANT, ATTORNEY,	OR AGENT							
	istiansen, Ph.D.	00500 PATENT TRADEMARK OFFICE							
Signature									
Date 5/6	102								
CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date specified below.									
	nan Adderson								
Signature Na	Market .	Date: 5/7/02							



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Orest W. Blaschuk et al.

Application No.

10/058,821

Filed

: January 29, 2002

For

COMPOUNDS AND METHODS FOR CANCER

THERAPY

Docket No.

: 100086.401C12

Date

: May 7, 2002

Commissioner for Patents Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached Forms PTO-1449. This application is a continuation and relies, under 35 U.S.C. § 120, on the earlier filing date of prior Application No. 09/357,717, filed July 20, 1999; which is a continuation-in-part of Application No. 09/248,074, filed February 10, 1999; which is a continuation-in-part of Application No. 08/996,679, filed December 23, 1997; which is a continuation-in-part of Application No. 08/893,534, filed July 11, 1997; which claims priority from U.S. Provisional Application No. 60/021,612, filed July 12, 1996.

References AP (on Page 1 of the attached Forms PTO-1449), BH (on Page 2 of the attached Forms PTO-1449), FC, and FG (on Page 6 of the attached Forms PTO-1449) were not submitted in these prior applications. Accordingly, copies of these references have been provided.

The references listed on the attached Forms PTO-1449 were submitted to and/or cited by the Patent and Trademark Office in this prior application and, therefore, are not required to be provided in this application. If the Examiner wishes, copies will be provided upon request.

As to any reference made of record on the attached Forms PTO-1449, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC

William T. Christiansen, Ph.D.

Registration No. 44,614

WTC:nka

Enclosures:

Postcard Form PTO/SB/21 Form PTO-1449 Cited References (4)

701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092

Phone: (206) 622-4900 Fax: (206) 682-6031

D:\NrPortbl\iManage\NATHANA\279280_1.DOC

FORM PTO-1449 (REV.7-80)

MAY 2 1 2002

INFORMATION DISCLOSURE STATEMENT (US LEADERS) ets if necessary)

S. DEPARTMENT OF COMMERCE

ATTY. DOSE ET NO. 100688.401C12 APPLICATION NO. 10/058,821

APPLICANTS

Orest W. Blaschuk et al.

FILING DATE January 29, 2002 **GROUP ART UNIT** Not Yet Assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,231,082	07/27/93	Schasteen	514	. 11	
	AB	5,352,667	10/04/94	Lider et al.	514	19	
	AC	5,510,628	04/23/96	Georger, Jr. et al.	257	32	
	AD	5,585,351	12/17/96	Ranscht	514	12	
	AE	5,591,432	01/07/97	Bronson et al.	424	130.1	
	AF	5,646,250	07/08/97	Suzuki	530	350	
	AG	5,665,590	09/09/97	Yang	435	6	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSI	LATION
 	- Joseph Literatura	DATE	COONIKI	YES	NO
 АН	EP 406 428 B1	01/09/91	ЕРО		
AI	WO 91/04745	04/18/91	PCT		
AJ	WO 92/08731	05/29/92	PCT		
AK	WO 94/11401	05/26/94	PCT		

	OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)
AL	Alexander et al., "An N-Cadherin-Like Protein Contributes to Solute Barrier Maintenance in Cultured Endothelium," <i>Journal of Cellular Physiology</i> 156: 610-618, 1993.
АМ	Ali et al., "Conformationally Constrained Peptides and Semipeptides Derived from RGD as Potent Inhibitors of the Platelet Fibrinogen Receptor and Platelet Aggregation," <i>J. Med. Chem.</i> 37(6): 769-780, 1994.
AN	Beesley et al., "The post-synaptic density: putative involvement in synapse stabilization via cahderins and covalent modification by ubiquitination," <i>Biochemical Society Transactions</i> 23: 59-64, 1995.
AO	Blakemore, "Remyelination of CNS axons by Schwann cells transplanted from the sciatic nerve," <i>Nature 266</i> : 68-69, 1977.
AP	Blaschuk et al., "A novel cadherin antagonist (Exherin) blocks human ovarian tumor growth in nude mice," <i>Molecular Biology of the Cell 10</i> : 72A, November 1999.

EXAMINER

DATE CONSIDERED

^{*} EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

U.S. DEPARTMENT OF COMMERCE FORM PTO-1449 PATENT AND TRADEMARK OFFICE (REV.7-80) MAY 2 1 2002 INFORMATION DISCOSURE STATEMENT

APPLICATION NO. ATTY. DOCKET NO. 10/058,821 100086.401C12 APPLICANTS

Orest W. Blaschuk et al.

FILING DATE January 29, 2002 GROUP ART UNIT Not Yet Assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	ВА	6,031,072					
	вв	6,169,071					
	ВС	6,207,639					

FOREIGN PATENT DOCUMENTS

 1	1		COLDUMN	TRANS	LATION
	DOCUMENT NUMBER	DATE	COUNTRY	YES	NO
BD	WO 96/40781	12/19/96	PCT		
BE	WO 97/07209	02/27/97	PCT		
BF	WO 98/02452	01/22/98	PCT		
BG	WO 98/45319	10/15/98	PCT		
вн	WO 99/33875	7/8/99	WIPO		<u> </u>

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

ВІ	Blaschuk and Farookhi, "Estradiol Stimulates Cadherin Expression in Rat Granulosa Cells," Developmental Biology 136: 564-567, 1989.
ВЈ	Blaschuk et al., "E-Cadherin, estrogens and cancer: is there a connection?" The Canadian Journal of Oncology 4(4): 291-301, 1994.
вк	Blaschuk et al., "Identification of a Cadherin Cell Adhesion Recognition Sequence," Developmental Biology 139: 227-229, 1990.
BL	Blaschuk et al., "Identification of a Conserved Region Common to Cadherins and Influenza Strain A Hemagglutinins," J. Mol. Biol. 211: 679-682, 1990.
ВМ	Bottenstein and Sato, "Growth of a rat neuroblastoma cell line in serum-free supplemented medium," <i>Proc.Natl. Acad. Sci. USA</i> 76(1): 514-517, 1979.
BN	Brecknell et al., "Bridge grafts of Fibroblast Growth Factor-4-Secreting Schwannoma Cells Promote Functional Axonal Regeneration in the Nigrostriatal Pathway of the Adult Rat," <i>Neuroscience 74</i> (3): 775-784, 1996.
во	Brockes et al., "Studies on Cultured Rat Schwann Cells. I. Establishment of Purified Populations from Cultures of Peripheral Nerve," <i>Brain Research</i> 165: 105-118, 1979.
BP	Brook et al., "Morphology and Migration of Cultured Schwann Cells Transplanted Into the

EXAMINER

Fimbria and Hippocampus in Adult Rats," *GLIA 9*: 292-304, 1993.

DATE CONSIDERED

Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in * EXAMINER: conformance and not considered. Include copy of this form with next communication to applicant(s).

Sheet 3 of 6**FORM PTO-1449** U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO. APPLICATION NO. (REV.7-80) ATENT AND TRADEMARK OFFICE MAY 2 1 2002 100086.401C12 10/058,821 APPLICANTS ZION DISCLOSURE STATEMENT Orest W. Blaschuk et al. Agyaral press if necessary) FILING DATE GROUP ART UNIT January 29, 2002 Not Yet Assigned **U.S. PATENT DOCUMENTS** *EXAMINER FILING DATE DOCUMENT NUMBER DATE NAME CLASS **SUBCLASS** INITIAL IF APPROPRIATE FOREIGN PATENT DOCUMENTS TRANSLATION DOCUMENT NUMBER COUNTRY YES OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) Byers et al., "Fibroblast Growth Factor Receptors Contain a Conserved HAV Region CA Common to Cadherins and Influenza Strain A Hemagglutinins: A Role in Protein-Protein Interactions?," Developmental Biology 152: 411-414, 1992. Cardarelli et al., "The Collagen Receptor α2β1, from MG-63 and HT1080 Cells, Interacts CB with a Cyclic RGD Peptide," The Journal of Biological Chemistry 267(32): 23159-23164, 1992. Carlstedt et al., "Nerve Fibre Regeneration Across the PNS-CNS Interface at the Root-CC Spinal Cord Junction," Brain Research Bulletin 22: 93-102, 1989. Cepek et al., "Expression of a candidate cadherin in T lymphocytes," Proc. Natl. Acad. Sci. CD USA 93: 6567-6571, 1996. Chuah et al., "Differentiation and survival of rat olfactory epithelial neurons in dissociated CE cell culture," Developmental Brain Research 60: 123-132, 1991. Craig et al., "Concept and Progress in the Development of RGD-Containing Peptide CF Pharmaceuticals," Biopolymers (Peptide Science) 37: 157-175, 1995. Doherty and Walsh, "CAM-FGF Receptor Interactions: A Model for Axonal Growth," CG Molecular and Cellular Neuroscience 8(Article No. 0049): 99-111, 1996. Doherty and Walsh, "Signal transduction events underlying neurite outgrowth stimulated by СН cell adhesion molecules," Current Opinion in Neurobiology 4: 49-55, 1994. Doherty et al., "Neurite Outgrowth in Response to Transfected N-CAM and N-Cadherin Reveals Fundamental Differences in Neuronal Responsiveness to CAMS," Neuron 6: 247-258, 1991. Duncan et al., "Transplantation of oligodendrocytes and Schwann cells into the spinal cord CJ of the myelin-deficient rat," Journal of Neurocytology 17: 351-360, 1988. Fok-Seang et al., "An analysis of astrocytic cell lines with different abilities to promote axon CK growth," Brain Research 689: 207-223, 1995. Fok-Seang et al., "Migration of Oligodendrocyte Precursors on Astrocytes and Meningeal CL Cells," Developmental Biology 171: 1-15, 1995. **EXAMINER** DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

Sheet <u>4</u> of <u>6</u> FORM PTO-1449 ATTY. DOCKET NO. APPLICATION NO. U.S. DEPARTMENT OF COMMERCE (REV.7-80) MAY 2 1 2002 PATENT AND TRADEMARK OFFICE 100086.401C12 10/058.821 APPLICANTS INFORM ETION DISCIPOSURE STATEMENT Orest W. Blaschuk et al. LA DEM Neets if necessary) FILING DATE GROUP ART UNIT January 29, 2002 Not Yet Assigned **U.S. PATENT DOCUMENTS** *EXAMINER FILING DATE DOCUMENT NUMBER DATE NAME CLASS SUBCLASS INITIAL IF APPROPRIATE FOREIGN PATENT DOCUMENTS TRANSLATION DOCUMENT NUMBER COUNTRY YES OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) Franz, "Percutaneous Absorption. On The Relevance Of In Vitro Data," The Journal of DA Investigative Dermatology 64(3): 190-195, 1975. Franz, "The Finite Dose Technique as a Valid in Vitro Model for the Study of Percutaneous DB Absorption in Man," Curr. Probl. Dermatol. 7: 58-68, 1978. Ghirnikar and Eng, "Astrocyte-Schwann Cell Interactions in Culture," GLIA 11: 367-377, DC Gumbiner et al., "The Role of the Cell Adhesion Molecule Uvomorulin in the Formation DD and Maintenance of the Epithelial Junctional Complex," The Journal of Cell Biology 107: 1575-1587, 1988. Iruela-Arispe et al., "Expression of SPARC during Development of the Chicken DE Chorioallantoic Membrane: Evidence for Regulated Proteolysis In Vivo," Molecular Biology of the Cell 6: 327-343, 1995. Laird et al., "Gap Junction Turnover, Intracellular Trafficking, and Phosphorylation of DF Connexin43 in Brefeldin A-treated Rat Mammary Tumor Cells," The Journal of Cell Biology 131(5): 1193-1203, 1995. Lee et al., "Expression of the Homotypic Adhesion Molecule E-Cadherin by Immature DG Murine Thymocytes and Thymic Epithelial Cells," Journal of Immunology 152: 5653-5659, 1994. Letourneau et al., "Interactions of Schwann Cells with Neurites and with Other Schwann DH Cells Involve the Calcium-dependent Adhesion Molecule, N-cadherin," Journal of Neurobiology 22(7): 707-720, 1991. Liuzzi and Lasek, "Astrocytes Block Axonal Regeneration in Mammals by Activating the DI Physiological Stop Pathway," Science 237: 642-645, 1987. Lutz et al., "Secondary Structure of the HAV Peptide Which Regulates Cadherin-Cadherin Interaction," Journal of Biomolecular Structure & Dynamics 13(3): 447-455, 1995. Matsuzaki et al., "cDNAs of Cell Adhesion Molecules of Different Specificity Induce DK Changes in Cell Shape and Border Formation in Cultured S180 Cells," The Journal of Cell Biology 110: 1239-1252, 1990. **EXAMINER** DATE CONSIDERED

Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in

* EXAMINER:

U.S. DEPARTMENT OF COMMERCE ATTY, DOCKET NO. APPLICATION NO. FORM PTO-1449 (REV.7-80) ATENT AND TRADEMARK OFFICE 100086.401C12 10/058,821 MAY 2 1 2002 APPLICANTS INFORMATION DISCLOSTRE STATEMENT Orest W. Blaschuk et al. loe several sheed of necessary) GROUP ART UNIT FILING DATE January 29, 2002 Not Yet Assigned U.S. PATENT DOCUMENTS *EXAMINER FILING DATE DATE SUBCLASS DOCUMENT NUMBER NAME CLASS INITIAL IF APPROPRIATE **FOREIGN PATENT DOCUMENTS** TRANSLATION DOCUMENT NUMBER COUNTRY YES NO OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) McCarthy and Vellis, "Preparation of Separate Astroglial and Oligodendroglial Cell EA Cultures from Rat Cerebral Tissue," J. Cell Biology 85: 890-902, 1980. Mege et al., "Construction of epithelioid sheets by transfection of mouse sarcoma cells with EB cDNAs for chicken cell adhesion molecules," Proc. Natl. Acad. Sci. USA 85: 7274-7278, 1988. Moran, "The Protein Delivery Service. Advances in technologies for delivering proteins EC and peptides in therapeutically useful forms," Pharmaceutical Forum Issue 6: 4-7, 1996. Munro and Blaschuk, Cell Adhesion and Invasion in Cancer Metastasis, R.G. Landes ED Company, Austin, TX, 1996, Chapter 3, "The Structure, Function and Regulation of Cadherins," pp. 17-34. Munro et al., "Characterization of Cadherins Expressed by Murine Thymocytes," Cellular EE Immunology 169(Article No. 0123): 309-312, 1996. Newton et al., "N-Cadherin Mediates Sertoli Cell-Spermatogenic Cell Adhesion," EF Developmental Dynamics 197: 1-13, 1993. Nose et al., "Localization of Specificity Determining Sites in Cadherin Cell Adhesion EG Molecules," Cell 61: 147-155, 1990. Orr, "Angiogenesis Research Offers New Approaches to Treatment of Disease," Genetic EΗ Engineering News, pp. 15-16, 42, May 1, 1996. Overduin et al., "Solution Structure of the Epithelial Cadherin Domain Responsible for ΕI Selective Cell Adhesion," Science 267: 386-389, 1995. Redies and Takeichi, "Cadherins in the Developing Central Nervous System: An Adhesive Code for Segmental and Functional Subdivisions," Developmental Biology 180: 413-423, 1996. Saffell et al., "Expression of a Dominant Negative FGF Receptor Inhibits Axonal Growth EK and FGF Receptor Phosphorylation Stimulated by CAMs," Neuron, pp. 231-242, February 1997. **EXAMINER DATE CONSIDERED** * EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE ATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. 100086.401C12					
INFORMATION DISCLETURE STATEMENT					APPLICANTS Orest W. Blaschuk et al.					
		The Payer hands if no	ecessary)		FILING DATE January 29, 2002			JP ART UNIT Yet Assig	ned	
	U.S. PATENT DOCUMENTS									
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLA	SS	SUBCLASS	FILING DATE IF APPROPRIATE	
			FOREI	GN PATEN	T DOCUMENTS					
		DOCUMENT NUMBER	DATE		COUNTRY				TRANSLATION YES NO	
		ОТНЕ	CR PRIOR A	RT (Including	Author, Title, Date, Pertinent Pa	ges, Etc.)		1	
	FA	1			Small RGD Peptide Fib			_	_	
	FD				y in Vitro," <i>J. Med. Ch</i> ell-cell adhesion by cad					
	FB	1995.	, Straotaru	- 04515 01 00	mreen adhesion by ead		3, 140	uiure 374.	321-331,	
	FC				ve role of cell adhesion	n mol	ecule	s in endon	netrisis,"	
	FD	Mol. Med. To			rin-Catenin Complexes	in H	ııman	Leukemis	. Cell	
	עז	Lines," J. Bio			_	, 111 14	alliul.			
	FE	Wickelgren,	"Breaking th	e Skin Bar	rier," <i>PS 12</i> : 86-88, 19	96.				
	FF				cell aggregation is afformutase," FEBS Letter					
	FG				f cyclic peptide antagonists suggests that N-cadherin					
		specificity is 4007-4012, F			cids that flank the HAV	√ mot	if," <i>J</i>	. Biol. Che	em. 275(6):	
	FH				GF Receptor Underlies	Neur	ite O	utgrowth S	Stimulated	
		by L1, N-CA	M, and N-C	adherin," N	<i>Jeuron 13</i> : 583-594, 19	94.				
	Williams et al., "The Primary Structure of Hen Ovotransferrin," Eur. J. Biochem. 122 303, 1982.							ı. <i>122</i> : 297-		
	FJ									
	FK									
	FL									
EXAMINE	R				DATE CONSIDERED					
* EXAMINE		nitial if reference consider	ed, whether or not	criteria is in cor	formance with MPEP 609. Draw	line thr	ough ci	tation if not in		
D:\NrPortbl\iMana	ige\NAT	onformance and not consi HANA\279245_1.DOC	dered. Include co	py of this form w	vith next communication to applic	cant(s).		Forms	Pat/P7-27 [01/31/01]	